Neptune Medical
"Creating the future of endoscopy"
Burlingame, California GI endoscopy device maker whose Triton 1 robotic colonoscopy system won FDA clearance in 2026; raised USD 97M Series D.
Neptune Medical is a venture-backed medical device company in Burlingame, California, that develops gastrointestinal endoscopy devices built on its proprietary Dynamic Rigidization technology, which lets an instrument switch between flexible and rigid states to control looping and stabilize the endoscope tip. Founder Alex Tilson is chief executive; the leadership team also includes chief technology officer David Mintz and chief financial officer Sandeep Yadav. The board is chaired by Fred Moll of Sonder Capital and includes Mir Imran of InCube Ventures, with board observers from Medtronic and J&J Development Corp.
The company's first FDA-cleared commercial product is Pathfinder, described as the first dynamically rigidizing overtube, used to manage loop formation and tip control during diagnostic and therapeutic GI procedures including colonoscopy. The company says Pathfinder has been used in more than 15,000 patients at US hospitals and academic medical centers. Variants named in its trademark list include Pathfinder SB and Pathfinder CR, the latter promoted for upper GI bleeding. Pathfinder is a non-robotic accessory and is the company's current revenue product.
Its robotics program is Triton, a GI robotic endoscopy system that combines Dynamic Rigidization with robotic control and AI in an ergonomic workstation for gastroenterologists. Triton is intended for screening, surveillance and diagnostic colonoscopy as well as complex lower-GI therapy such as endoscopic mucosal resection and endoscopic submucosal dissection, with navigation and control throughout the colon. In September 2026 the company announced that the Triton 1 System had received US FDA clearance; the pathway and clearance number were not disclosed. The company describes the clearance as a step toward commercial deployment, and at the time of collection the official Triton site still stated that the device was not available for sale.
Clinical evidence comes from CARE 1, a 50-patient first-in-human study presented at Digestive Disease Week 2026. The company reports no adverse events, a 100 percent cecal intubation rate, a 54 percent adenoma detection rate against a cited industry benchmark of 35 percent, no need for patient repositioning or abdominal pressure, and a 67 percent reduction in average endoscopist workload measured with the NASA Task Load Index.
In August 2024 Neptune Medical raised a 97 million US dollar Series D, with significant contributions from Sonder Capital and Olympus Corporation of the Americas alongside existing and new investors, to support development of its GI robotics platform. No cumulative funding total is published on the official site.
Primary type & automation activities this supplier delivers:
Triton Robotic Endoscopy System
Robotic GI endoscopy system with Dynamic Rigidization for diagnostic and therapeutic colonoscopy, including EMR and ESD.
More related news
- 1
- 2
- 3
-
4
ISMR 2027: Medical Robotics Symposium, Nashville RobotToday · Oct 06, 2026
-
5
Robotics Summit & Expo 2027 | Jun 2–3, Boston RobotToday · Oct 05, 2026
- 6
- 7
- 8
- 9
-
10
RobotToday Weekly September 14 – 18, 2026 RobotToday · Sep 19, 2026
- 11
- 12
-
13
Innovation Works Venture Expo 2026: 58 Pittsburgh Startups Pitch to Investors RobotToday · Sep 16, 2026
- 14
-
15
RobotToday Weekly Briefing August 31 – September 4, 2026 RobotToday · Sep 05, 2026
-
16
Robotics Investing: Intuitive Surgical or Unitree? RobotToday · Aug 31, 2026
-
17
ROBOTTODAY WEEKLY BRIEFING August 24 – 28, 2026 RobotToday · Aug 29, 2026
-
18
WRC 2026 Robot Systems: 149 Companies That Build Robots RobotToday · Aug 27, 2026
-
19
WRC 2026 Exhibitor Map: 248 Robotics Companies Mapped RobotToday · Aug 26, 2026
- 20
Contact Neptune Medical
WEBSITE
https://neptunemedical.comHEADQUARTERS
United States
Company Facts
Founded
2016
Primary Role
Manufacturer
Company Size
employees 100-500
Primary Region
North America
Annual Sales
-
Funding Stage
Growth / Late-Stage VC
Funding Total
-
